StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Cost Realignment Program by Quarter

Cost Realignment Program — Total expected program one-time costs ($M) ($M)

Pfizer Cost Realignment Program: $4,700M in Q2 2026, up 51.6% from a year earlier.

Latest, Q2 2026
4,700
Period ended Jun 28, 2026
Change on a year earlier
+51.6%
3,100 in Q2 2025
History
6 quarters
Since Q1 2025
Sources
6
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Note 3 — Restructuring Charges & Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCost Realignment Program — Total expected program one-time costs ($M) ($M)Year on yearSource
Q2 2026Jun 28, 20264,700+51.6%Form 10-Q (filed 2026-08-04) ↗
Q1 2026Mar 29, 20264,700+51.6%Form 10-Q (filed 2026-05-05) ↗
Q4 2025Dec 31, 20254,700–Form 10-K (filed 2026-02-26) ↗
Q3 2025Sep 28, 20254,700–Form 10-Q (filed 2025-11-04) ↗
Q2 2025Jun 29, 20253,100–Form 10-Q (filed 2025-08-05) ↗
Q1 2025Mar 30, 20253,100–Form 10-Q (filed 2025-05-05) ↗

Cite this data

StockData. (2026). Pfizer Cost Realignment Program ($M), quarterly Q1 2025–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/restruct-exp-realign

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.